Cobalamin (Vitamin) : Physiology, Evidence, and Clinical Translation

Cobalamin: The Organometallic Cofactor of Isomerization, Methyl Transfer, and Neuronal Integrity

Cobalamin, vitamin B12, is a water-soluble vitamin that is unique among the micronutrients in its structural complexity and in the narrowness of its biological sources. It is the only vitamin to contain a metal ion, cobalt, coordinated at the center of a corrin ring, a tetrapyrrole macrocycle that is related to but distinct from the porphyrins of heme and chlorophyll. The cobalt-carbon bond at the heart of the two active coenzyme forms, methylcobalamin and adenosylcobalamin, is the only known organometallic bond in biology, and its chemistry enables two specific and essential reactions in the human organism: the methyl transfer from 5-methyltetrahydrofolate to homocysteine that regenerates methionine, and the isomerization of methylmalonyl-CoA to succinyl-CoA that completes the catabolism of odd-chain fatty acids and branched-chain amino acids. Cobalamin is not synthesized by plants, fungi, or animals. It is produced exclusively by a select group of bacteria and archaea, and the human supply is obtained through a complex and exquisitely specialized system of transport proteins and receptors that extract the vitamin from the diet and deliver it to the tissues. This monograph is written for the clinician and scientist who seek to understand cobalamin not as a simple injectable for fatigue, but as an organometallic cofactor whose deficiency produces a devastating neurological syndrome that can be permanently disabling if missed, whose absorption is dependent on a gastric glycoprotein whose failure defines the disease pernicious anemia, and whose status is a determinant of the integrity of the myelin sheath, the fidelity of DNA synthesis, and the homeostasis of the one-carbon cycle.

---

Part 1. The Structural and Chemical Identity of Cobalamin

Cobalamin is a molecule of architectural grandeur. The corrin ring is a contracted porphyrin, missing one of the four methine bridges that connect the pyrrole rings of the porphyrin macrocycle, giving it a direct carbon-carbon bond between two of the pyrrole subunits. The corrin ring coordinates a central cobalt atom through four nitrogen atoms, and the cobalt is further coordinated by a lower axial ligand, a 5,6-dimethylbenzimidazole nucleotide that is attached to the corrin ring through an aminopropanol linker and a ribose phosphate, and by an upper axial ligand that defines the specific cobalamin species. In methylcobalamin, the upper ligand is a methyl group. In adenosylcobalamin, it is a 5'-deoxyadenosyl group. In cyanocobalamin, the synthetic form that is used in supplements and fortification, it is a cyano group. Cyanocobalamin is not a naturally occurring form; it is a stable, semi-synthetic derivative that is converted to the active coenzyme forms in the body by the removal of the cyanide ligand and its replacement with a methyl or adenosyl group.

The chemistry of the cobalt-carbon bond is the key to the biological function of cobalamin. The bond is weak and can be cleaved homolytically, with one electron going to the cobalt and the other to the carbon, generating a carbon radical and a reduced cobalt species. This radical chemistry is the basis for the adenosylcobalamin-dependent isomerization reactions, in which a hydrogen atom and a substituent on adjacent carbon atoms are exchanged. The bond can also be cleaved heterolytically, with the cobalt retaining both electrons and the carbon departing as an electrophilic methyl group, the chemistry of the methylcobalamin-dependent methyltransferase reactions.

1A. The Biosynthetic Impossibility and the Microbial Origin of Cobalamin

The biosynthesis of cobalamin is a feat of microbial biochemistry that requires approximately thirty enzymatic steps and two distinct pathways, the aerobic and the anaerobic, that converge on the corrin ring. This pathway is present only in certain bacteria and archaea. No eukaryote, including plants, fungi, and animals, can synthesize cobalamin. The vitamin B12 that is present in animal-derived foods is the product of the microbial synthesis in the rumen of herbivores, the intestinal microbiota of animals, or the environmental bacteria that colonize the food chain. The human requirement for cobalamin is met by the consumption of meat, poultry, fish, shellfish, eggs, and dairy products. The strict vegetarian and vegan diets, which exclude all animal-derived foods, are deficient in cobalamin unless fortified foods or supplements are consumed.

The recommended dietary allowance for adults is 2.4 micrograms per day, with an increase to 2.6 micrograms per day during pregnancy and 2.8 micrograms per day during lactation. The body stores of cobalamin are substantial, approximately 2 to 5 milligrams, the majority of which is in the liver, and the daily loss is small, approximately 0.1 percent of the total body pool. The consequence of this efficient enterohepatic recirculation is that a dietary deficiency of cobalamin, as occurs in strict veganism, takes years to manifest clinically, while a defect in absorption, as occurs in pernicious anemia, produces a deficiency within months to a few years.

1B. The Absorption, Transport, and Cellular Delivery of Cobalamin

The absorption of dietary cobalamin is a multi-step, receptor-mediated process that is unique in human biology and that is exquisitely vulnerable to disruption at each step.

In the stomach, dietary cobalamin is released from its protein matrix by the action of pepsin and hydrochloric acid and is bound to haptocorrin, a glycoprotein of salivary and gastric origin that binds cobalamin with high affinity at acidic pH. The haptocorrin-cobalamin complex passes into the duodenum, where the haptocorrin is digested by pancreatic proteases, releasing the cobalamin. The free cobalamin is then bound by intrinsic factor, a glycoprotein that is secreted by the gastric parietal cells, the same cells that secrete hydrochloric acid. The intrinsic factor-cobalamin complex is resistant to proteolytic digestion and is transported to the terminal ileum, where it is bound and internalized by the cubam receptor, a heterodimer of cubilin and amnionless, on the surface of the ileal enterocyte. The intrinsic factor is degraded, and the cobalamin is exported across the basolateral membrane into the portal circulation, bound to transcobalamin II, the transport protein that delivers cobalamin to all tissues.

The uptake of cobalamin from the plasma into cells is mediated by the transcobalamin II receptor, which internalizes the transcobalamin II-cobalamin complex by receptor-mediated endocytosis. The transcobalamin II is degraded in the lysosome, and the cobalamin is released into the cytoplasm, where it is processed to the active coenzyme forms. The methyl group of methylcobalamin is transferred to homocysteine by methionine synthase in the cytoplasm, and the adenosyl group of adenosylcobalamin is generated in the mitochondrion, where it serves as the cofactor for methylmalonyl-CoA mutase.

---

Part 2. The Coenzyme Biology: Two Reactions in the Human Organism

The human organism uses cobalamin for exactly two enzymatic reactions, a remarkable economy of function for a molecule of such structural complexity. The consequences of a failure of these two reactions, however, are protean and severe.

2A. Methionine Synthase and the Methylation Cycle

Methionine synthase is the enzyme that catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate (5-methyl-THF) to homocysteine, yielding methionine and tetrahydrofolate (THF). The methyl group is transferred from the 5-methyl-THF to the cobalt atom of methylcobalamin, forming a transient methyl-cobalt intermediate, and then from the methylcobalamin to the sulfur atom of homocysteine. This is the only reaction in the human body that can convert 5-methyl-THF back to THF, the folate form that can enter the one-carbon pool and support nucleotide synthesis. This is the biochemical basis of the "methyl trap" hypothesis: in cobalamin deficiency, methionine synthase is inactive, the folate pool is trapped in the 5-methyl-THF form, and the synthesis of the other folate coenzymes, including the 5,10-methylene-THF required for thymidylate synthesis, is impaired. This produces a functional folate deficiency, a failure of DNA synthesis, and the megaloblastic anemia that is the hematological hallmark of cobalamin deficiency, indistinguishable from the anemia of folate deficiency.

The methionine product of the methionine synthase reaction is the precursor for S-adenosylmethionine (SAM), the universal methyl donor for the methylation of DNA, histones, myelin basic protein, and the phospholipids of the myelin sheath. A failure of methionine synthase reduces the SAM pool, impairing the methylation reactions that are essential for the maintenance of the myelin sheath and for the regulation of gene expression. This is the biochemical basis for the neurological manifestations of cobalamin deficiency, the subacute combined degeneration of the spinal cord, the peripheral neuropathy, and the cognitive impairment.

2B. Methylmalonyl-CoA Mutase and the Catabolism of Odd-Chain Fatty Acids

Methylmalonyl-CoA mutase is a mitochondrial enzyme that catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA, a reaction that requires adenosylcobalamin. The adenosylcobalamin generates a 5'-deoxyadenosyl radical that abstracts a hydrogen atom from the substrate, initiating a radical rearrangement that exchanges a hydrogen atom and a carbonyl-CoA group on adjacent carbon atoms. This is the final step in the catabolism of odd-chain fatty acids, which generate propionyl-CoA as the terminal product of beta-oxidation, and of the branched-chain amino acids isoleucine and valine. In cobalamin deficiency, methylmalonyl-CoA mutase activity is impaired, methylmalonyl-CoA accumulates, and its metabolite, methylmalonic acid, is excreted in the urine and is elevated in the plasma. The measurement of methylmalonic acid is a sensitive and specific functional test for cobalamin deficiency at the tissue level.

The accumulation of methylmalonyl-CoA and its metabolic products, including methylmalonic acid and propionic acid, is thought to contribute to the neurological toxicity of cobalamin deficiency. Methylmalonic acid is a competitive inhibitor of the enzyme succinate dehydrogenase, the Complex II of the mitochondrial electron transport chain, and it may impair the mitochondrial energy metabolism of the neuron. The incorporation of the abnormal odd-chain fatty acids and branched-chain fatty acids into the myelin lipids, in the absence of methylmalonyl-CoA mutase activity, produces an abnormal, unstable myelin that is the pathological substrate of the demyelination that characterizes the cobalamin-deficient spinal cord and peripheral nerve.

---

Part 3. The Clinical Taxonomy of Cobalamin Deficiency

Cobalamin deficiency is a clinical chameleon. Its manifestations span the hematopoietic, neurological, and psychiatric domains, and the presentation can be dominated by any one of these systems, leading to diagnostic delay and error.

3A. Pernicious Anemia: The Autoimmune Basis of Cobalamin Malabsorption

Pernicious anemia is the classic cause of cobalamin deficiency, an autoimmune disease in which the gastric parietal cells are destroyed by a cell-mediated and antibody-mediated attack. The autoantibodies are directed against the gastric H+/K+-ATPase, the proton pump of the parietal cell, and against the intrinsic factor itself. The destruction of the parietal cells produces an achlorhydria, a failure of intrinsic factor secretion, and a cobalamin deficiency that progresses inexorably in the absence of treatment. Pernicious anemia is most common in individuals of Northern European and African descent, and it is associated with other autoimmune diseases, including autoimmune thyroiditis, vitiligo, and type 1 diabetes. The diagnosis is made by the presence of anti-intrinsic factor antibodies, which are specific but insensitive, and by the clinical picture of a macrocytic anemia, a low serum cobalamin, and an elevated serum methylmalonic acid and homocysteine.

3B. The Neurological Syndrome: Subacute Combined Degeneration of the Spinal Cord

The neurological manifestation of cobalamin deficiency is a myeloneuropathy, the subacute combined degeneration of the spinal cord, in which the dorsal columns, the lateral corticospinal tracts, and the peripheral nerves are demyelinated. The clinical presentation is a progressive, symmetric, distal paresthesia, a loss of proprioception and vibration sense in the lower extremities, a sensory ataxia with a positive Romberg sign, and, in the later stages, a spastic paraparesis with hyperreflexia and extensor plantar responses. The neurological examination reveals a combination of upper motor neuron signs from the corticospinal tract involvement and lower motor neuron signs from the peripheral neuropathy, a pattern that is distinctive and that should prompt an immediate measurement of serum cobalamin.

The neurological syndrome can occur in the absence of anemia, and this is a critical clinical point. The administration of folic acid to a patient with undiagnosed cobalamin deficiency can correct the megaloblastic anemia while allowing the neurological disease to progress, potentially to the point of irreversible spinal cord damage. The clinician must never treat a macrocytic anemia with folic acid without first excluding cobalamin deficiency.

3C. The Neuropsychiatric Presentation: Dementia, Depression, and Psychosis

Cobalamin deficiency can present with cognitive impairment, memory loss, and a dementia that mimics Alzheimer's disease. The psychiatric presentation can be depression, mania, or a psychosis with hallucinations and paranoia. The mechanism is thought to involve a failure of the SAM-dependent methylation of the myelin basic protein and the neurotransmitters in the brain. The recognition of cobalamin deficiency as a reversible cause of dementia and psychiatric illness is a critical clinical imperative, as the response to cobalamin therapy is often dramatic in the early stages of the disease.

3D. The Hyperhomocysteinemia and the Vascular Risk

The elevation of plasma homocysteine that accompanies cobalamin deficiency is a biomarker of the functional failure of methionine synthase. The hyperhomocysteinemia is a risk factor for venous thromboembolism and, in epidemiological studies, for cardiovascular disease and stroke. The treatment of cobalamin deficiency normalizes the homocysteine, but, as discussed in the folate monograph, the lowering of homocysteine with B-vitamin therapy has not been shown to reduce the risk of cardiovascular events in randomized controlled trials.

---

Part 4. The Evidence Mapped by Quality and Clinical Application

The clinical evidence for cobalamin is organized around the treatment of the deficiency state, the management of the specific clinical syndromes that are caused by the deficiency, and the controversy over the use of cobalamin in the absence of a documented deficiency.

4A. The Treatment of Cobalamin Deficiency: Parenteral and Oral Routes

The standard treatment of cobalamin deficiency, regardless of the cause, is the parenteral administration of cyanocobalamin or hydroxocobalamin. Hydroxocobalamin is the preferred agent in many countries because it is retained in the body for a longer duration than cyanocobalamin, due to its binding to plasma proteins. The standard regimen is an intramuscular injection of 1000 micrograms of hydroxocobalamin or cyanocobalamin, administered daily or every other day for the first week, then weekly for the first month, and then monthly for life. The response to therapy is a reticulocytosis within 5 to 7 days, a correction of the anemia within 4 to 8 weeks, and a gradual improvement in the neurological symptoms over weeks to months, though a residual neurological deficit may persist if the diagnosis was delayed.

The alternative to parenteral therapy is high-dose oral cobalamin, 1000 to 2000 micrograms per day, a dose that is sufficient to bypass the intrinsic factor-dependent absorption pathway through the passive diffusion of approximately 1 percent of the ingested dose. This is an effective and more convenient therapy for patients who are compliant and who can be monitored for a response, but the parenteral route is the standard of care for pernicious anemia and for patients with severe neurological disease.

4B. Cobalamin and the "B12 Shot" for Fatigue

The use of parenteral cobalamin for the treatment of fatigue, malaise, and non-specific symptoms in patients who do not have a documented cobalamin deficiency is a common clinical practice that is not supported by evidence. The placebo effect of an injection is substantial, and the sense of increased energy that is reported by some patients after a cobalamin injection is likely a combination of a placebo response and the correction of a marginal, subclinical cobalamin status that is below the detection threshold of the standard serum cobalamin assay. The measurement of methylmalonic acid and homocysteine, the functional markers of cobalamin status, should be performed in patients who are being evaluated for a cobalamin-responsive fatigue syndrome.

4C. The Cobalamin-Nitrous Oxide Interaction

Nitrous oxide, the inhalational anesthetic and recreational drug, irreversibly oxidizes the cobalt atom of cobalamin from the active Co(I) state to the inactive Co(III) state, inactivating methionine synthase. A single exposure to nitrous oxide in a patient with a marginal cobalamin status can precipitate an acute neurological syndrome of myeloneuropathy and cognitive impairment. This is a clinical emergency that is treated with high-dose parenteral cobalamin. The recognition of the nitrous oxide-cobalamin interaction is a critical point in the evaluation of a patient who presents with an acute or subacute myeloneuropathy, particularly in the setting of a recent surgery or recreational nitrous oxide use.

---

Part 5. A Clinical Dosing Compendium

The dosing of cobalamin is determined by the clinical indication, the route of administration, and the urgency of the response.

5.1. Evidence-Based and Guideline-Supported Protocols

Treatment of Cobalamin Deficiency. Hydroxocobalamin 1000 micrograms intramuscularly, daily or every other day for the first week, then weekly for the first month, then monthly for life. For oral therapy, cyanocobalamin 1000 to 2000 micrograms per day.

Pernicious Anemia. The parenteral regimen is the standard of care, as the intrinsic factor-dependent absorption is permanently absent.

Dietary Cobalamin Deficiency in Veganism. Oral cyanocobalamin 50 to 100 micrograms per day, or a single dose of 1000 micrograms per week, is sufficient to maintain cobalamin status.

Nitrous Oxide-Induced Myeloneuropathy. Hydroxocobalamin 1000 micrograms intramuscularly, daily for 5 to 7 days, followed by the standard monthly maintenance regimen.

5.2. Universal Principles Governing Cobalamin Supplementation

The Diagnosis of Cobalamin Deficiency Is a Biochemical Diagnosis, Not a Clinical One. The serum cobalamin concentration, the methylmalonic acid, and the homocysteine are the diagnostic tests. The clinical response to cobalamin therapy is not a diagnostic criterion. Every patient who is being treated with cobalamin should have a documented biochemical deficiency before the initiation of therapy, except in the specific emergency of a nitrous oxide-induced myeloneuropathy.

The Serum Cobalamin Concentration Can Be Misleading. A serum cobalamin concentration in the low-normal range, 200 to 300 picograms per milliliter, does not exclude a functional cobalamin deficiency at the tissue level. The measurement of methylmalonic acid is the gold standard for the assessment of tissue cobalamin status. A persistently elevated methylmalonic acid in the presence of a normal serum cobalamin is an indication for a therapeutic trial of cobalamin.

The Neurological Consequences of a Missed Diagnosis Are Irreversible. The subacute combined degeneration of the spinal cord, if untreated, progresses to a permanent paraplegia and a loss of bowel and bladder function. The window of reversibility is measured in weeks to months. The clinician who evaluates a patient with a progressive, symmetric, sensory ataxia and a loss of proprioception must measure the serum cobalamin, methylmalonic acid, and homocysteine on the first visit.

---

Part 6. The Unresolved Frontier

Three specific questions define the current limit of cobalamin science.

What Is the Significance of the Transcobalamin Polymorphisms and the Holotranscobalamin Assay? The transport of cobalamin in the plasma and its delivery to the tissues is dependent on transcobalamin II, a protein that is polymorphic in the human population. The measurement of holotranscobalamin, the transcobalamin II-cobalamin complex that is the biologically available fraction of the plasma cobalamin, is proposed as a more sensitive marker of cobalamin status than the total serum cobalamin. The clinical utility of the holotranscobalamin assay, and the significance of the transcobalamin polymorphisms, are not fully defined.

What Is the Role of Cobalamin in the Modulation of the Gut Microbiome and the Gut-Brain Axis? The gut microbiome is both a consumer and a producer of cobalamin. The composition of the microbiome can influence the host cobalamin status, and the host cobalamin status can influence the composition of the microbiome. The interplay between dietary cobalamin, the microbiome, and the host neurological and immunological function is an emerging frontier that has implications for the understanding of the non-classical effects of cobalamin on the brain and the immune system.

Can the Neuroprotective Effect of Cobalamin Be Harnessed for the Treatment of Neurodegenerative Disease? The observation that cobalamin deficiency produces a demyelinating disease of the brain and spinal cord, and that cobalamin is a cofactor for the SAM-dependent methylation of the myelin basic protein, raises the question of whether supraphysiological doses of cobalamin, or of a cobalamin analog that crosses the blood-brain barrier more efficiently, can support myelin repair in multiple sclerosis or in the leukodystrophies. This is a therapeutic hypothesis that has not been adequately tested.

---

Part 7. Synthesis for an Evidence-Based Approach

Cobalamin is a vitamin of singular biochemical elegance, an organometallic cofactor that enables the radical isomerization and the methyl transfer reactions that are essential for the catabolism of odd-chain fatty acids and for the regeneration of methionine from homocysteine. Its deficiency is a clinical syndrome that spans the hematopoietic, neurological, and psychiatric domains, a syndrome that is preventable and treatable but that, if missed, produces a permanent and devastating disability. The absorption of cobalamin is dependent on a gastric glycoprotein, the intrinsic factor, whose autoimmune destruction defines the disease pernicious anemia, and the transport of cobalamin to the tissues is mediated by a dedicated carrier protein, transcobalamin II, whose genetic variation may determine the individual's susceptibility to the clinical manifestations of the deficiency.

The clinical use of cobalamin is defined by the principle that every patient who is treated with the vitamin should have a documented biochemical deficiency, except in the specific emergency of a nitrous oxide-induced myeloneuropathy. The use of cobalamin for non-specific symptoms of fatigue and malaise, in the absence of a deficiency, is not supported by evidence and is a distraction from the search for the true cause of the patient's symptoms.

The unresolved questions in cobalamin biology are the significance of the transcobalamin polymorphisms for the delivery of the vitamin to the brain, the role of the microbiome in the host cobalamin economy, and the potential for cobalamin to support myelin repair in the demyelinating diseases. The investigation of these questions will determine whether cobalamin, a vitamin that is already essential for the maintenance of the myelin sheath, can become a therapeutic agent for its restoration.